These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 6334139

  • 1. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E, Chriqui-Zeira E, Kyriazis AP.
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [Abstract] [Full Text] [Related]

  • 2. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K, Pellis NR, Kahan BD.
    Cancer Res; 1988 Jan 01; 48(1):101-8. PubMed ID: 3257158
    [Abstract] [Full Text] [Related]

  • 3. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K, O'Donnell RW, Cockett AT.
    J Biol Response Mod; 1988 Feb 01; 7(1):43-53. PubMed ID: 3259620
    [Abstract] [Full Text] [Related]

  • 4. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E, Ben-Aziz R, Shiloni E.
    Isr J Med Sci; 1988 Feb 01; 24(9-10):494-504. PubMed ID: 3264551
    [Abstract] [Full Text] [Related]

  • 5. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP, Ottow RT, Eggermont AM, Marquet RL, Sugarbaker PH.
    Cancer Detect Prev; 1988 Feb 01; 12(1-6):81-90. PubMed ID: 3263202
    [Abstract] [Full Text] [Related]

  • 6. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

  • 7. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
    Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA.
    J Immunol; 1984 Apr 15; 132(4):2123-8. PubMed ID: 6607956
    [Abstract] [Full Text] [Related]

  • 8. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R, Kamdar SJ, Duffy T, Edison L.
    J Immunol; 1993 Jan 01; 150(1):177-84. PubMed ID: 8417123
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy of tumor-derived heat shock protein 70 immunotherapy combining interleukin-2 on tumor-bearing mice.
    Fu Q, Meng F, Shen X, Guo R.
    Chin Med J (Engl); 2003 Feb 01; 116(2):288-91. PubMed ID: 12775249
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA.
    J Biol Response Mod; 1984 Oct 01; 3(5):501-11. PubMed ID: 6389777
    [Abstract] [Full Text] [Related]

  • 11. Potential for specific cancer therapy with immune T lymphocytes.
    Cheever MA, Greenberg PD, Fefer A.
    J Biol Response Mod; 1984 Oct 01; 3(2):113-27. PubMed ID: 6233396
    [Abstract] [Full Text] [Related]

  • 12. Chemoimmunotherapy of murine mammary adenocarcinomas.
    Ames IH.
    Anticancer Res; 2004 Oct 01; 24(4):2249-56. PubMed ID: 15330169
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P, De Meyer M, Leroy P, Rousseau C, Acres B.
    Cancer Gene Ther; 2001 May 01; 8(5):321-32. PubMed ID: 11477452
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM, Steller EP, Ottow RT, Matthews W, Sugarbaker PH.
    J Natl Cancer Inst; 1987 Nov 01; 79(5):983-90. PubMed ID: 3500357
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S, Chou T, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3891-8. PubMed ID: 3486223
    [Abstract] [Full Text] [Related]

  • 18. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L.
    Cancer Res; 1995 Nov 01; 55(21):4941-9. PubMed ID: 7585534
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
    Eberlein TJ, Rosenstein M, Spiess PJ, Rosenberg SA.
    J Natl Cancer Inst; 1982 Jul 01; 69(1):109-16. PubMed ID: 6980314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.